Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

Abroad (travel likely)RecruitingPHASE2

Conditions

Anaplastic Large Cell Lymphoma, ALK-Positive

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

New York Medical College, Valhalla, New York, United States
Contact: Study coordinator (Lauren Harrison, RN, MSN) · lauren_harrison@nymc.edu · 617-285-7844
Contact: Study coordinator (Mitchell S Cairo, MD) · mitchell_cairo@nymc.edu · 914-594-2150

Study leads

Mitchell S Cairo, MD
Principal Investigator
New York Medical College

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors

Anaplastic Large Cell Lymphoma, ALK-Positive · Inflammatory Myofibroblastic Tumor · Other Solid Tumor

Abroad (travel likely)RecruitingPHASE1, PHASE2

Paris, France · Utrecht, Netherlands

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

CD30-Positive Diffuse Large B-Cell Lymphoma · Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type · Anaplastic Large Cell Lymphoma, ALK-Positive

Abroad (travel likely)RecruitingPHASE1

Houston, United States · Houston, United States

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Anaplastic Lymphoma Kinase · Anaplastic Large Cell Lymphoma

Abroad (travel likely)RecruitingPHASE1

Basking Ridge, United States · Middletown, United States

A Registry for People With T-cell Lymphoma

T-cell Lymphoma · NK-Cell Lymphoma · T-cell Prolymphocytic Leukemia

Abroad (travel likely)Recruiting

Duarte, United States · San Diego, United States